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The utility of live attenuated vaccines for controlling HIV epidemics
is being debated. Live attenuated HIV vaccines (LAHVs) could be
extremely effective in protecting against infection with wild-type
strains, but may not be completely safe as the attenuated strain
could cause AIDS in some vaccinated individuals. We present a
theoretical framework for evaluating the consequences of the
tradeoff between vaccine efficacy (in terms of preventing new
infections with wild-type strains) and safety (in terms of vaccine-
induced AIDS deaths). We use our framework to predict, for
Zimbabwe and Thailand, the epidemiological impact of 1,000
different (specified by efficacy and safety characteristics) LAHVs.
We predict that paradoxically: (i) in Zimbabwe (where transmission
is high) LAHVs would significantly decrease the AIDS death rate,
but (ii) in Thailand (where transmission is low) exactly the same
vaccines (in terms of efficacy and safety characteristics) would
increase the AIDS death rate. Our results imply that a threshold
transmission rate exists that determines whether any given LAHV
has a beneficial or a detrimental impact. We also determine the
vaccine perversity point, which is defined in terms of the fraction
of vaccinated individuals who progress to AIDS as a result of the
vaccine strain. Vaccination with any LAHV that causes more than
5% of vaccinated individuals to progress to AIDS in 25 years would,
even 50 years later, lead to perversity (i.e., increase the annual AIDS
death rate) in Thailand; these same vaccines would lead to de-
creases in the annual AIDS death rate in Zimbabwe.
L ive attenuated vaccines (due to their high protective efficacy,low cost, and simple immunization schedules) have been used
successfully to control smallpox, polio, and measles epidemics
(1, 2). Preliminary attempts have been made to develop a live
attenuated HIV vaccine (LAHV) (3–6); however, the debate
about the potential utility of developing LAHVs has been
controversial, mainly due to concerns that have arisen about
vaccine safety (3, 4, 7–9). The major safety concern is that even
a very attenuated strain of HIV (if used as a LAHV) could
actually cause AIDS in some fraction of vaccinated individuals
(4, 5). Live attenuated polio vaccine has caused some cases of
paralytic poliomyelitis (10), and any live attenuated vaccine has
the potential to cause disease. Studies in macaques of the closely
related simian immunodeficiency virus have shown that live
attenuated strains can be highly effective in protecting against
infection with the wild-type strain (4, 11), but that some ma-
caques develop AIDS as a result of the attenuated strain (5, 12).
Concern about the potential safety of LAHVs has been height-
ened by a recent report of the natural history of HIV infection
in a cohort of gay men in Australia (13). Some of these men were
infected with a naturally attenuated strain of HIV. Long-term
follow-up studies of this cohort have shown that this strain of
HIV, although attenuated, can cause immune deterioration (13).
The design of a LAHV therefore presents a formidable
challenge.
The efficacy and safety of LAHVs will be determined by phase
III clinical trials; however, the safety effects of any LAHV will
need to be understood at the epidemic level before any candidate
vaccine can be considered as a potential epidemic control agent.
Here we present a mathematical model that provides a theoret-
ical framework that can be used for LAHVs to predict the
tradeoff between vaccine efficacy (in terms of preventing new
infections with wild-type HIV) and vaccine safety effects (in
terms of vaccine-induced AIDS deaths) at the epidemic level.
We evaluate the consequences of this tradeoff by using our
model to predict the potential epidemiological impact of vacci-
nation with a variety of LAHVs in Thailand and Zimbabwe.
Specifically, we use our model to address two research questions:
(i) could vaccination with a LAHV lead to the eradication of the
wild-type strain of HIV? and (ii) what impact would a mass
vaccination campaign with a LAHV have on the annual AIDS
death rate? We discuss the implications of our results for vaccine
design, phase III clinical trials, and epidemic control strategies.
Mathematical models of HIV vaccines have been used: (i) to
calculate vaccine efficacy and vaccination coverage levels for
eradicating HIV (using a prophylactic non-LAHV) (14–16), (ii)
to design phase III trials (17–19), (iii) to evaluate the effect of
changes in risk behavior on vaccination campaigns (15, 20), and
(iv) to determine the degree of vaccine-induced cross-immunity
that would be necessary to control multiple subtypes (20–22).
These analyses (14–22) have evaluated the consequences of
vaccines that do not have the potential to cause AIDS. Here, we
present a theoretical framework that enables us to model the
effects of a mass vaccination campaign that uses a LAHV. We
use our model to explicitly quantify the tradeoff between the
potential efficacy (in terms of reducing the number of new
infections with the wild-type strain) and the safety effects (in
terms of vaccine-induced AIDS deaths) of a LAHV. We predict
the potential epidemiological impact of mass vaccination with a
variety of LAHVs (with different efficacy and safety character-
istics) in two countries with very different HIV epidemics:
Zimbabwe (where the current HIV prevalence is 25%) (http:!!
www.unaids.org!hivaidsinfo!documents.html) and Thailand
(where the current HIV prevalence is 2%) (http:!!www.unaids.
org!hivaidsinfo!documents.html).
Methods
Mathematical Model of Mass Vaccination with a LAHV. Our model
tracks the temporal dynamics of individuals in five groups:
susceptible individuals (X), unvaccinated individuals infected
with wild-type HIV (YW), individuals uninfected with the wild-
type strain but infected with the vaccine strain (either by
vaccination or transmission of the vaccine strain) (YV), individ-
uals dually infected with the vaccine and the wild-type strain
(YVW), and individuals with AIDS (A). Our model is specified by
five coupled ordinary differential equations (see Appendix). A
flow diagram of the model is given in Fig. 4, which is published
Abbreviations: LAHV, live attenuated HIV vaccine; pdf, probability density function; VPP,
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as supplemental material on the PNAS web site, www.pnas.org;
the five colored boxes represent the five groups (i.e., state
variables) and the black arrows show the processes that move
individuals from one state to another state. Our modeling
framework allows us to analyze the epidemiological conse-
quences of cross-interactions among strains; similar frameworks
have been used to analyze multiple strain dynamics for myxoma,
influenza, and tuberculosis (23–28) or to evaluate the effects of
vaccination and cross-immunity (29).
We model vaccine efficacy by assuming that a LAHV can have
two beneficial effects: (i) a degree effect (i.e., the vaccine induces
some degree of protection against infection with wild-type
strains), and (ii) a therapeutic effect (i.e., the vaccine reduces the
wild-type disease progression rate in dually infected individuals).
Dually infected individuals (YVW) are individuals that are vac-
cinated (i.e., they are originally YV individuals), but subsequently
become infected with the wild-type strain. We assume that these
dually infected individuals (YVW) (due to the presence of the
vaccine strain) may have a lower viral load than unvaccinated
HIV-infected individuals (YW). Reductions in viral load will
decrease the disease progression rate, thus YVW individuals (in
comparison with YW individuals) will have a slower disease
progression rate (30, 31). We model the safety effect of a LAHV
by assuming that the vaccine strain can cause a fraction of the
vaccinated individuals (who remain uninfected with the wild-
type strains) to slowly progress to AIDS. We also include the
possibility that the vaccine strain could be transmitted from
vaccinated individuals (YV) to susceptible individuals (X).
Initial Conditions. To set the initial conditions for our analyses we
used our model equations (assuming no vaccination), Latin
hypercube sampling methodology, and parameter estimates
based on probability density functions (pdfs) to estimate the
current annual AIDS death rate in Thailand and Zimbabwe. We
used the following pdfs: average survival time with AIDS (1!!A)
(pdf: 9 months - 1 year - 18 months) (32, 33), average infec-
tiousness (i.e., transmission probability) of wild-type HIV per
sexual partnership ("W) (pdf: 0.05 to 0.1 to 0.2) (34), and average
disease progression rate to AIDS due to infection with wild-type
strains (vW) (pdf: range from 50% progression to AIDS in 7.5
years to 50% progression in 10 years) (33, 35–37). To obtain
country-specific estimates we used current estimates of the
population size of sexually active adults [Zimbabwe 5,560,000
(http:!!www.unaids.org!hivaidsinfo!documents.html) and
Thailand 34,433,000 (http:!!www.unaids.org!hivaidsinfo!
documents.html)] and estimates of the average sexually active
lifespan (31 years in Zimbabwe (http:!!www.unaids.org!
hivaidsinfo!documents.html) and 49 years in Thailand (http:!!
Fig. 1. Predictions of the epidemiological impact of 1,000 different LAHVs. Annual AIDS death rates are plotted in the form of box plots; the median values
are shown in red. Uncertainty analysis predictions (1,000 simulations for each country) of the annual AIDS death rates (per 100,000 individuals) that are the result
of infection with the wild-type strain of HIV are plotted for Zimbabwe (A) and Thailand (B). Uncertainty analysis predictions (1,000 simulations for each country)
of the annual AIDS death rates (per 100,000 individuals) that are the result of the LAHV strain are plotted for Zimbabwe (C) and Thailand (D).












www.unaids.org!hivaidsinfo!documents.html). The parameter c
(average rate of acquiring new sex partners) was derived as a
dependent variable. We compared our estimates with reported
data on the current annual AIDS death rate in Zimbabwe and
Thailand.
Uncertainty Analysis of Analytical Equilibrium Results. We used our
model and conducted an uncertainty analysis of the endemic
equilibria to predict whether mass vaccination with a LAHV
could eradicate wild-type HIV in Zimbabwe and!or Thailand.
To make these predictions we analyzed our model to obtain
analytical expressions for the endemic equilibria states (see
supplemental Appendix, which is published on the PNAS web
site). These analyses revealed that if the vaccination coverage
level (p) was greater than zero then either a coexistence endemic
state would be reached (where both the wild-type HIV strain and
the LAHV strain would be present), or the wild-type strains
would be eradicated and only the LAHV strain would reach an
endemic state. We derived analytical expressions for these two
possible endemic equilibria (i.e., coexistence or wild-type erad-
ication). Then we used uncertainty analysis (based on Latin
hypercube sampling, which is a type of stratified Monte Carlo
sampling scheme; refs. 38–43) to obtain 1,000 different sets of
parameter estimates to define the characteristics of 1,000 dif-
ferent mass vaccination campaigns. Mass vaccination campaigns
were defined in terms of vaccine efficacy (in terms of # and g),
vaccine safety (vV), and vaccination coverage level (p); each
symbol specifies a parameter in the model, see Appendix for
precise definitions of each parameter. The pdfs that we used for
#, g, vV, and p are described in the next section. We then
determined for each of these 1,0000 parameter sets (by using the
derived analytical expressions for the endemic equilibria)
whether they would stabilize at either the coexistence or the
wild-type eradication state. We derived country-specific results
by using the appropriate demographic parameters for Zimbabwe
and Thailand. For further details see the supplemental Appendix.
Prediction Methodology: Time-Dependent Uncertainty Analysis. To
predict the potential impact of LAHVs on the annual AIDS
death rate, we analyzed our model by using time-dependent
uncertainty analyses based on Latin hypercube sampling. Pre-
viously we have used this analysis to make predictions for other
Fig. 2. Predictions of the epidemiological impact of 1,000 different LAHVs.
Annual AIDS death rates are plotted in the form of box plots; the median
values are shown in red. Uncertainty analysis predictions (1,000 simulations for
each country) of the total annual AIDS death rates (per 100,000 individuals)
are plotted for Zimbabwe (A) and Thailand (B). The total annual AIDS death
rate equals the annual AIDS deaths that are caused by the wild-type strain plus
the annual AIDS deaths that are caused by the vaccine strain.
Fig. 3. Time-dependent uncertainty analysis predictions showing the effect
of vaccine safety (in terms of the percentage of the vaccinated individuals that
progress to disease in 25 years as a result of vaccination with a LAHV) on the
total annual AIDS death rates per 100,000; 1,000 predictions are shown for
Zimbabwe (A) and Thailand (B) at each time point. Dark blue data show the
initial conditions prevaccination (which is time 0); these initial conditions are
model estimates of the current annual AIDS death rates in these countries.
Pink data are predicted data 10 years after vaccination. Yellow data are
predicted data 50 years after vaccination, and the light blue data are predicted
data 200 years after vaccination. The VPP at 50 years (VPP50) for Thailand is
shown.
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infectious disease models (38–43); details are given elsewhere
(38–43). By using uncertainty analysis we were able to use pdfs,
rather than single values, to specify parameter estimates. For
each analysis, each parameter was assigned 1,000 different values
sampled from the specified pdf; values were chosen by dividing
the pdf for each parameter into 1,000 equi-probable intervals,
and then sampling the pdf (randomly and without replacement)
1,000 times. The pdf for each parameter was sampled indepen-
dently. We explored the potential effects of LAHVs with a fairly
wide range of efficacy and safety characteristics. This method-
ology enabled us to generate (for each country) 1,000 different
simulations; where each simulation had a different vaccination
coverage level and a different LAHV (as specified by the efficacy
and safety characteristics). For each simulation we assumed that
a mass vaccination campaign (with a coverage level of p) would
be initiated at time 0 and a fraction (p) of new susceptibles would
be vaccinated annually.
We predicted the effects of mass vaccination campaigns (with
follow-up programs) that would vaccinate anywhere from 80%
to 95% of susceptibles (range of pdf: 0.95 ! p ! 0.8). Only a
LAHV that has performed extremely well in terms of efficacy in
phase III trials is likely to be licensed. Therefore we assumed that
the LAHVs used in our vaccination campaigns would have fairly
high efficacy characteristics. To specify the pdf for LAHV
efficacy we assumed that: (i) the ‘‘degree’’ of vaccine-induced
protection (#) against infection with the wild-type strains was
between 50% and 95% (range of pdf: 0.95 ! # ! 0.5), and that
(ii) the ‘‘therapeutic’’ effect of the vaccine ($) in dually infected
individuals reduced the wild-type disease progression rate from
1- to 10-fold (range of pdf: 1 ! $ ! 0.1). The long-term risks of
LAHV (in terms of the risk of developing AIDS due to the
vaccine strain) might not be apparent in short-term phase III
trials as disease progression rates are slow, therefore we evalu-
ated the consequences of a wide range of risks. Risk was defined
in terms of the vaccine-induced disease progression rate (vV); we
evaluated the consequences of vaccines that could cause any-
where from 1% to 10% (with a most likely value of 5%) of the
vaccinated individuals to progress to AIDS in 25 years. These
vaccine-induced disease progression rates (pdf: minimum 1%,
peak 5%, maximum 10% in 25 years) translated into a range in
the annual progression rate to AIDS of 5 to 40 individuals per
10,000 vaccinated individuals. Finally, we assumed that, although
the vaccine strain could be transmitted, the infectiousness of the
vaccine strain was 10- to 1,000-fold (with a peak at 100) less
infectious than the wild-type strain (range of pdf: 0.10 ! % !
0.001).
Results
The current annual AIDS death rate in Zimbabwe is 1,987 per
100,000 individuals (http:!!www.unaids.org!hivaidsinfo!
documents.html), and in Thailand it is 159 per 100,000 individ-
uals (http:!!www.unaids.org!hivaidsinfo!documents.html). The
median values from our estimates for the initial conditions for
our analyses closely matched the reported data (predicted
median estimate for Zimbabwe was 1,982 per 100,000, and
predicted median estimate for Thailand was 176 per 100,000).
Predictions: Could a LAHV Eradicate Wild-Type HIV? All of our 1,000
predictions (for Thailand and Zimbabwe) gave the same result:
the wild-type strain of HIV would be eradicated, and the
prevalence of the vaccine strain would rise to an endemic steady
state. Hence, our results revealed that mass vaccination with a
LAHV eventually would result in the replacement of the virulent
pathogen (wild-type HIV) with the relatively avirulent pathogen
(the LAHV strain). Further calculations revealed that at this new
endemic steady state, the vaccine strain could be eradicated
simply by stopping vaccination, because the basic reproductive
number (R0
V) of the LAHV strain (which is calculated from our
model) is significantly less than one.
Predictions: What Effect Would a LAHV Have on the Annual AIDS Death
Rate? We then determined the time frame for eradication.
Time-dependent uncertainty analysis of our model revealed that
eradication of wild-type HIV would take several decades in both
countries [Fig. 1A (Zimbabwe) and Fig. 1B (Thailand)]. The
current annual AIDS death rate in Zimbabwe (Fig. 1A) is
significantly higher than in Thailand (Fig. 1B). However, in both
countries AIDS deaths (due to infection with wild-type strains
of HIV) decreased quickly and dramatically because vaccination
coverage level was high and the LAHVs were extremely effective
in blocking transmission [Fig. 1A (Zimbabwe) and Fig. 1B
(Thailand)]. The annual AIDS death rate (due to the vaccine) in
Thailand and Zimbabwe reached the same endemic level [Fig.
1C (Zimbabwe) and Fig. 1D (Thailand)].
Our analyses revealed the epidemic-level consequences of
both the efficacy (Fig. 1 A and B) and the safety (Fig. 1 C and
D) effects of LAHVs. We then combined these efficacy and
safety predictions to calculate whether the net effect (in terms of
the total annual AIDS death rate) of vaccination with a LAHV
would be beneficial or detrimental. The total annual AIDS death
rate " AIDS deaths due to wild-type strains of HIV # AIDS
deaths that are vaccine-induced. The net effect of vaccination in
Zimbabwe was always very beneficial; the total annual AIDS
death rate decreased substantially over time for all of the 1,000
simulations (Fig. 2A). In contrast, in Thailand the total annual
AIDS death rate actually increased over time in the majority of
the simulations (Fig. 2B); thus the net effect of vaccination in this
country was often detrimental.
Determining the Impact of Vaccine Safety on the Total Annual AIDS
Death Rate. We quantified the impact of vaccine safety (defined
in terms of the percentage of vaccinated individuals who would
progress to AIDS as a result of the vaccine strain) on increasing
the total annual AIDS death rate. In Zimbabwe the total annual
AIDS death rate decreased over time in all of the 1,000
simulations; the predicted prevaccination (i.e., the current)
annual AIDS death rates are shown by the dark blue data in Fig.
3A. At any given time point after mass vaccination campaigns
were begun, the total annual AIDS death rate decreased as
vaccine safety increased; results are shown after 10 years (pink
data), 50 years (yellow data), and 200 years (light blue data) of
vaccination in Fig. 3A. In contrast, in Thailand after vaccination
campaigns were begun the total annual AIDS death rate actually
increased over time in some of the simulations (Fig. 3B); the
predicted prevaccination (i.e., the current) annual AIDS death
rates are shown by the dark blue data in Fig. 3B. Almost all of
the 1,000 different LAHVs led to an initial increase in the total
annual AIDS death rate in Thailand, as can be seen from the
pink data (which are predicted data after 10 years of vaccination)
in Fig. 3B. However, after several decades, some of the vaccines
had increased (whereas others had decreased) the total annual
AIDS death rate in Thailand; the outcome depended on vaccine
safety (Fig. 3B).
LAHVs have beneficial epidemic-level effects (by reducing
transmission) and also detrimental effects (by causing vaccine-
induced AIDS deaths). We used our predicted data to determine
the vaccine perversity point (VPP) for Thailand (Fig. 3B); the
VPP is a threshold defined in terms of the vaccine safety level.
The VPP is defined (at any specified time) to be the vaccine-
induced disease progression rate at which the beneficial epidem-
ic-level effects caused by the vaccine equal the detrimental
epidemic-level effects caused by the vaccine; thus at the VPP the
net impact on the total annual AIDS death rate is zero. Almost
all of the 1,000 different LAHVs led to an initial increase in the
total annual AIDS death rate in Thailand, hence the VPP (at 10












years) occurs at approximately 2% (which is the point at which
the pink data cross the dark blue data in Fig. 3B). At 50 years,
the value of the VPP in Thailand is approximately 5% (i.e., a
vaccine-induced disease progression rate of 5% in 25 years); this
VPP (VPP50) occurs at the point at which the yellow data cross
the dark blue data in Fig. 3B. LAHVs that had a faster
vaccine-induced disease progression rate than the VPP50 caused
more harm than good in Thailand (even 50 years later) as they
increased the total annual AIDS death rate (Fig. 3B). Con-
versely, LAHVs that had a slower vaccine-induced disease
progression rate than the VPP50 caused more good than harm in
Thailand as they decreased (after several decades) the total
annual AIDS death rate (Fig. 3B). Mass vaccination with any
LAHV that caused more than 5% of vaccinated individuals to
progress to AIDS in 25 years led to perversity (i.e., an increase
in the annual AIDS death rate) in Thailand (Fig. 3B), but not in
Zimbabwe (Fig. 3A). There is no VPP for Zimbabwe (at any time
point) (Fig. 3A), because all of the LAHVs that we ‘‘tested’’ in
that country led to a decrease in the annual AIDS death rate
(i.e., all of the predicted data for Zimbabwe, at every time point,
lay below the dark blue data at time 0; Fig. 3A).
Discussion
Our theoretical framework enables us to conduct a ‘‘biological
risk-benefit’’ analysis for any particular LAHV for any specified
HIV epidemic. We evaluated the potential epidemiological
consequences of 1,000 different LAHVs, where the vaccines
differed on the basis of efficacy and safety characteristics.
Vaccination campaigns with exactly the same LAHVs may prove
beneficial in one country (as we showed for Zimbabwe), but
could be detrimental in another (as we showed for Thailand).
These results may seem paradoxical, because in both countries
we used LAHVs that had exactly the same efficacy and safety
characteristics. We obtained these apparently paradoxical re-
sults, because the effectiveness of LAHVs (unlike the effective-
ness of prophylactic non-LAHV) is determined not only by the
efficacy and safety characteristics of the vaccine, but also by the
transmission rate. The transmission rate determines (for any
given LAHV) the tradeoff between the vaccine’s efficacy and
safety characteristics. Hence the transmission rate determines
whether the vaccine has a beneficial or a detrimental net impact
(where net impact is defined in terms of the total annual AIDS
death rate). In Zimbabwe the transmission rate is high, thus the
benefits of reducing transmission (i.e., high efficacy) outweigh
the safety consequences. In Thailand the transmission rate is
fairly low, thus the safety consequences can outweigh the
benefits of reducing transmission. Our results imply that a
threshold transmission rate (TTR) exists. If the transmission rate
is greater than the TTR, then the efficacy effect of a LAHV
outweighs the safety effect. Conversely, if the transmission rate
is less than the TTR, then the safety effect outweighs the efficacy
effect. Our model can be used to determine the exact value of
the TTR for any specified vaccine efficacy and safety level.
Our results bring to light several issues that need to be
considered regarding the utility of LAHVs as potential epidemic
control agents. First, our results indicate that LAHVs may only
be useful for controlling HIV in countries where there are very
high transmission rates (i.e., where the transmission rate is
significantly greater than the TTR). Second, our results imply
that if LAHVs are to be used then it will be necessary to decide
on multiple goals for epidemic control strategies (44) rather than
simply to consider only eradication. For both Zimbabwe and
Thailand our analyses show that vaccination with a fairly effec-
tive LAHV could lead to the eradication of wild-type HIV;
however, on the way to eradication the total annual AIDS death
rate could increase in Thailand. It is obviously unacceptable to
achieve eradication at the price of an increased AIDS death rate.
Thus, our results suggest that it may be necessary (if LAHVs are
to be used as epidemic control agents) to design fairly complex
vaccination strategies that can achieve both eradication of
wild-type HIV and a significant reduction in the annual AIDS
death rate. Optimal control theory could be used to design more
complex vaccination strategies that can simultaneously attain
multiple goals. Such an approach would entail specifying an
objective function to maximize the benefits and minimize the
costs of vaccination. This methodology has been used previously
for designing optimal treatment strategies for HIV-infected
individuals on chemotherapy (45). Third, our results imply that
it will be necessary to implement large-scale surveillance systems
to determine when wild-type strains of HIV have been eradi-
cated; after wild-type HIV has been eradicated all of the AIDS
deaths would be the result of the vaccine strain.
Our results also have important practical implications for
vaccine design, and the implementation of phase III clinical
trials. Our model can be used (as we have shown) to determine
the VPP for a LAHV used in any particular geographic region.
Our results show that only LAHVs that induce almost no disease
should be considered for use, particularly in low incidence areas.
It may be possible to develop a very safe LAHV, but it may only
be possible at a cost to efficacy; increasing the attenuation of
vaccine strains (in the simian immunodeficiency virus model)
tends to increase vaccine safety, but to decrease efficacy (3, 4, 7).
We have quantified the extremely high safety standards that
must be met before LAHV can be considered safe as epidemic
control agents. Very large numbers of participants will need to
be monitored for many years to determine whether such high
levels of vaccine safety have been attained in a phase III clinical
trial. We have determined that the net effect of any LAHV is
very dependent on the transmission rate. Thus it will be neces-
sary to conduct many phase III clinical trials of any candidate
LAHV in a variety of geographic locations where there is a wide
variety of transmission rates. Testing LAHVs could involve
conducting many more phase III trials than the testing of
prophylactic non-LAHV. If phase III trials of LAHVs are
conducted in only high transmission areas then these vaccines
could look very beneficial. However, if these vaccines were then
used to control epidemics where there is only moderate or low
transmission then these vaccines could increase the severity of
the epidemic.
It appears unlikely that the HIV pandemic will be con-
trolled—particularly in Africa—unless effective vaccines are
developed (36, 46). If prophylactic non-LAHV are used they will
reduce transmission and produce only beneficial epidemic-level
effects; perverse effects will only occur if risky behavior increases
(15, 20). The effectiveness of high efficacy prophylactic non-
LAHV can be assessed by evaluating our predictions for the
annual AIDS death rate and considering only the efficacy effects
of LAHVs [Fig. 3A (Zimbabwe) and Fig. 3B (Thailand)]. These
vaccines would eradicate HIV in both Thailand and Zimbabwe
without producing any perverse effects, unless risky behavior
increased. Unfortunately, it is very difficult to develop such
vaccines. It is possible that LAHVs may be the most effective
HIV vaccines that are developed.
We have shown that LAHVs potentially could be very effec-
tive as epidemic control agents, but that LAHVs should have an
extremely low risk of causing AIDS in vaccinated individuals. In
addition, there are several other safety concerns that need to be
addressed when considering LAHVs. For example, a LAHV may
cause insertional mutagenesis, or the LAHV strain could in-
crease in pathogenicity by recombining with a superinfecting
wild-type strain. Our theoretical framework can be expanded to
evaluate the consequences of these additional safety concerns.
Clearly, there are many ethical issues that need to be debated
when considering LAHVs as epidemic control agents. We have
shown that while effective LAHVs could eradicate wild-type
HIV, these vaccines could also (in countries where the incidence
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rate is low) increase the severity of the HIV epidemic. It is
therefore possible that LAVHs may only be considered for use
in developing countries (where incidence rates are high), but not
in developed countries (where incidence rates are low). How-
ever, any mass vaccination campaign based on LAVHs will need
to be designed by considering the HIV pandemic rather than
simply a country-specific epidemic, because country-specific
HIV epidemics are linked. Thus it appears likely that the
discussion of the development and the potential utility of
LAHVs for control of the HIV pandemic will become even more
controversial.
Appendix
The mathematical model is specified by the following five
ordinary differential equations:
dX!dt & $1 ' p%( ' X$c)V * c)W * !%, [1]
dYV!dt & p( * Xc)V ' $1 ' #%YVc)W ' YV$vv * !%, [2]
dYW!dt & Xc)W ' YW$vw * !%, [3]
dYVW!dt & $1 ' #%Yvc)W ' YVW$vvw * !%, [4]
dA!dt & YWvw * YVWvvw * YVvv ' A$! * !A%. [5]
) specifies the per-capita risk of infection with either the vaccine
strain ()V) or the wild-type strain ()W). ) is calculated as the
product of the probability of selecting an infectious sex partner
and the infectiousness of HIV per sexual partnership ("), which
differs for the wild-type strain ("W) and the vaccine strain ("V).
Only YV individuals can transmit the LAHV strain; the param-
eter % specifies the degree to which the vaccine strain is less
infectious than the wild-type strain (hence "V " % "W). We
assume that dually infected individuals (YVW) can only transmit
the wild-type strain; LAHVs may reduce the infectiousness of
the wild-type strain in these dually infected individuals by a
factor g, but in our current analyses we set g " 1.0. Hence, )V "
"V (YV!NSA) and )W " "W [(YW # gYVW)!NSA]; NSA specifies
the size of the sexually active population and is equal to X #
YW # YVW # YV.
The remaining parameter definitions are: p " the fraction of
new susceptibles vaccinated, ( " the number of new susceptibles
that join the sexually active population per unit time, c " the
average rate of acquiring new sex partners, 1!! " the average
period of acquisition of new sex partners, 1!!A " the average
survival time with AIDS, # " the degree of protection that the
LAHV provides against infection with the wild-type strain, v "
the progression rate to AIDS in individuals infected with the
LAHV strain (vv), the wild-type strain (vw), or both strains (vvw),
1!!A " the average survival time from AIDS to death. The
disease progression rates are related by the expression vvw " $
vw; where $ specifies the vaccine-induced degree of reduction in
the wild-type disease progression rate.
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